B.A. Damoiseaux-Volman

Dr. B.A. Damoiseaux-Volman


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2021 in JMIR Medical Informatics
Verified
Journal Article
Open access
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
NVNathalie van der Velde
Nathalie van der Velde
SRSil G Ruige
Sil G Ruige
JRJohannes A Romijn
Johannes A Romijn
AAAmeen Abu-Hanna
Ameen Abu-Hanna
SMStephanie Medlock
Stephanie Medlock
Background: Clinical decision support systems (CDSSs) form an implementation strategy that can facilitate and support health care professionals in the care of older hospitalized patients.Objective: Our study aims to systematically review the effects of CDSS interventions in older hospitalized patients. As a secondary aim, we aim to summarize the implementation and design factors described in effective and ineffective interventions and identify gaps in the current literature.Methods: We conducted a systematic review with a search strategy combining the categories older patients, geriatric topic, hospital, CDSS, and intervention in the databases MEDLINE, Embase, and SCOPUS. We included controlled studies, extracted data of all reported outcomes, and potentially beneficial design and implementation factors. We structured these factors using the Grol and Wensing Implementation of Change model, the GUIDES (Guideline Implementation with Decision Support) checklist, and the two-stream model. The risk of bias of the included studies was assessed using the Cochrane Collaboration’s Effective Practice and Organisation of Care risk of bias approach.Results: Our systematic review included 18 interventions, of which 13 (72%) were effective in improving care. Among these interventions, 8 (6 effective) focused on medication review, 8 (6 effective) on delirium, 7 (4 effective) on falls, 5 (4 effective) on functional decline, 4 (3 effective) on discharge or aftercare, and 2 (0 effective) on pressure ulcers. In 77% (10/13) effective interventions, the effect was based on process-related outcomes, in 15% (2/13) interventions on both process- and patient-related outcomes, and in 8% (1/13) interventions on patient-related outcomes. The following implementation and design factors were potentially associated with effectiveness: a priori problem or performance analyses (described in 9/13, 69% effective vs 0/5, 0% ineffective interventions), multifaceted interventions (8/13, 62% vs 1/5, 20%), and consideration of the workflow (9/13, 69% vs 1/5, 20%).Conclusions: CDSS interventions can improve the hospital care of older patients, mostly on process-related outcomes. We identified 2 implementation factors and 1 design factor that were reported more frequently in articles on effective interventions. More studies with strong designs are needed to measure the effect of CDSS on relevant patient-related outcomes, investigate personalized (data-driven) interventions, and quantify the impact of implementation and design factors on CDSS effectiveness.Trial Registration: PROSPERO (International Prospective Register of Systematic Reviews): CRD42019124470; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=124470.

15 December 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
SMStephanie Medlock
Stephanie Medlock
DMDelanie van der Meulen
Delanie van der Meulen
JBJesse de Boer
Jesse de Boer
JRJohannes A. Romijn
Johannes A. Romijn
AAAmeen Abu-Hanna
Ameen Abu-Hanna
The aim of this scoping review is to summarize approaches and outcomes of clinical validation studies of clinical decision support systems (CDSSs) to support (part of) a medication review. A literature search was conducted in Embase and Medline. In total, 30 articles validating a CDSS were ultimately included. Most of the studies focused on detection of adverse drug events, potentially inappropriate medications and drug‐related problems. We categorized the included articles in three groups: studies subjectively reviewing the clinical relevance of CDSS's output (21/30 studies) resulting in a positive predictive value (PPV) for clinical relevance of 4–80%; studies determining the relationship between alerts and actual events (10/30 studies) resulting in a PPV for actual events of 5–80%; and studies comparing output of CDSSs to chart/medication reviews in the whole study population (10/30 studies) resulting in a sensitivity of 28–85% and specificity of 42–75%. We found heterogeneity in the methods used and in the outcome measures. The validation studies did not report the use of a published CDSS validation strategy. To improve the effectiveness and uptake of CDSSs supporting a medication review, future research would benefit from a more systematic and comprehensive validation strategy.

18 October 2021 in Age and Ageing
Verified
Journal Article
Open access
PDF file
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
KRKimmy Raven
Kimmy Raven
DSDanielle Sent
Danielle Sent
SMStephanie Medlock
Stephanie Medlock
JRJohannes A Romijn
Johannes A Romijn
NVNathalie van der Velde
Nathalie van der Velde
Objective: to investigate the effect of potentially inappropriate medications (PIMs) on inpatient falls and to identify whether PIMs as defined by STOPPFall or the designated section K for falls of STOPP v2 have a stronger association with inpatient falls when compared to the general tool STOPP v2. Methods: a retrospective observational matching study using an electronic health records dataset of patients (≥70 years) admitted to an academic hospital (2015–19), including free text to identify inpatient falls. PIMs were identified using the STOPP v2, section K of STOPP v2 and STOPPFall. We first matched admissions with PIMs to those without PIMs on confounding factors. We then applied multinomial logistic regression analysis and Cox proportional hazards analysis on the matched datasets to identify effects of PIMs on inpatient falls. Results: the dataset included 16,678 hospital admissions, with a mean age of 77.2 years. Inpatient falls occurred during 446 (2.7%) admissions. Adjusted odds ratio (OR) (95% confidence interval (CI)) for the association between PIM exposure and falls were 7.9 (6.1–10.3) for STOPP section K, 2.2 (2.0–2.5) for STOPP and 1.4 (1.3–1.5) for STOPPFall. Adjusted hazard ratio (HR) (95% CI) for the effect on time to first fall were 2.8 (2.3–3.5) for STOPP section K, 1.5 (1.3–1.6) for STOPP and 1.3 (1.2–1.5) for STOPPFall. Conclusions: we identified an independent association of PIMs on inpatient falls for all applied (de)prescribing tools. The strongest effect was identified for STOPP section K, which is restricted to high-risk medication for falls. Our results suggest that decreasing PIM exposure during hospital stay might benefit fall prevention, but intervention studies are warranted.

2 December 2020 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
SMStephanie Medlock
Stephanie Medlock
KRKimmy Raven
Kimmy Raven
DSDanielle Sent
Danielle Sent
JRJohannes A. Romijn
Johannes A. Romijn
AAAmeen Abu-Hanna
Ameen Abu-Hanna
Purpose: To investigate prevalence, independent associations, and variation over time of potentially inappropriate prescriptions in a population of older hospitalized patients. Methods: A longitudinal study using a large dataset of hospital admissions of older patients (≥ 70 years) based on an electronic health records cohort including data from 2015 to 2019. Potentially inappropriate medication (PIM) and potential prescribing omission (PPO) prevalence during hospital stay were identified based on the Dutch STOPP/START criteria v2. Univariate and multivariate logistic regression were used for analyzing associations and trends over time. Results: The data included 16,687 admissions. Of all admissions, 56% had ≥ 1 PIM and 58% had ≥ 1 PPO. Gender, age, number of medications, number of diagnoses, Charlson score, and length of stay were independently associated with both PIMs and PPOs. Additionally, number of departments and number of prescribing specialties were independently associated with PIMs. Over the years, the PIM prevalence did not change (OR = 1.00, p = .95), whereas PPO prevalence increased (OR = 1.08, p < .001). However, when corrected for changes in patient characteristics such as number of diagnoses, the PIM (aOR = 0.91, p < .001) and PPO prevalence (aOR = 0.94, p < .001) decreased over the years. Conclusion: We found potentially inappropriate prescriptions in the majority of admissions of older patients. Prescribing relatively improved over time when considering complexity of the admissions. Nevertheless, the high prevalence shows a clear need to better address this issue in clinical practice. Studies seeking effective (re)prescribing interventions are warranted.

23 November 2022 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
NSNatasja M. van Schoor
Natasja M. van Schoor
SMStephanie Medlock
Stephanie Medlock
JRJohannes A. Romijn
Johannes A. Romijn
NVNathalie van der Velde
Nathalie van der Velde
AAAmeen Abu-Hanna
Ameen Abu-Hanna

17 December 2024 in Journal of Clinical Neuroscience
Verified
Journal Article
Open access
SPSusanna R. Prins
Susanna R. Prins
SVSarah E. Vermeer
Sarah E. Vermeer
BDB.A. Damoiseaux-Volman
B.A. Damoiseaux-Volman
SPSimone Priester-Vink
Simone Priester-Vink
NVNathalie van der Velde
Nathalie van der Velde
RBRenske M. Van Den Berg-Vos
Renske M. Van Den Berg-Vos
Limited evidence exists on the efficacy and safety of statins in older ischemic stroke or transient ischemic attack patients, particularly in frail individuals. Studies often exclude frail patients, limiting insights on optimal treatments for the entire older population. This review aims to evaluate the effect of statins for secondary prevention on quality of life and functioning in older patients following an ischemic stroke or transient ischemic attack, as these outcomes are aligned with the treatment goals of this patient population. We performed a systematic review and meta-analysis by searching four major databases up to June 6th, 2023. Studies were included if they involved statins, assessed quality of life or functioning, focused on older patients, and addressed ischemic stroke or transient ischemic attack. We included six randomized controlled trials and 16 cohort studies, totaling 66.273 patients. Mean or median age ranged from 65 to 79 years. Age ranges were not provided, and frailty status was not reported. One trial examined the effect of statins on QoL, yielding mixed results. Regarding the effect of statins on functioning, two trials reported positive effects, two found no effect, and two yielded mixed results. The meta-analysis of cohort studies indicated a positive association between statins and functioning (effect size: 0.43, CI 0.28-0.58). Methodological quality was poor, primarily due to confounding, participant selection and the allocation of patients into intervention groups. We could not draw definitive conclusions regarding the effect of statins and QoL or functioning in older stroke patients. Mixed results were found in RCTs, and while a positive association between statins and functional outcome was observed in cohort studies, this should be interpreted with caution due to methodological limitations. Future research should focus on age-specific analyses and adequate representation of frail individuals to clarify this issue.